Prianka Singh

发表

Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.

Robert A. Mendes, D. Dills, C. Zheng, 2015, Journal of managed care & specialty pharmacy.

Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.

N. Parikh, B. Sill, Jeffrey D. Miller, 2019, The American journal of managed care.

Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.

J. Ajani, S. Kanters, I. Kim, 2022, European journal of cancer.

Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents

J. Shaw, B. Feinberg, J. Kish, 2020, Journal of medical economics.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

J. Ajani, T. Zander, A. Lièvre, 2021, The New England journal of medicine.

Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib

D. Stenehjem, N. Parikh, B. Sill, 2017 .

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany

T. Gauler, A. Dietz, L. McDonald, 2021, Head & neck.

Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

A. Amin, O. Baser, J. Trocio, 2015 .

Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view

O. Baser, J. Trocio, J. Mardekian, 2016, Journal of medical economics.

Caregiver burden by treatment and clinical characteristics of patients with glioblastoma

Jennie W. Taylor, C. Ulrich, H. Colman, 2021, Supportive Care in Cancer.

Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.

A. Norden, H. Dastani, M. Botteman, 2019, Neuro-oncology practice.

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study

K. Davies, N. Robert, S. Annavarapu, 2021, CNS oncology.

Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting

J. Trocio, H. Henk, J. Mardekian, 2018, Current medical research and opinion.

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

B. Bennett, G. Taylor‐Stokes, S. Curtis, 2021, BMC cancer.

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States

K. Harrington, J. Shaw, R. Haddad, 2020, Journal of medical economics.

Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy

M. Bonafede, N. Parikh, B. Sill, 2019, Journal of Gastrointestinal Cancer.

Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain

B. Bennett, M. Contente, Prianka Singh, 2021, Advances in Therapy.

Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study.

Jennie W. Taylor, H. Colman, A. Chakravarti, 2023, Future oncology.

Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation

J. Trocio, Jay Lin, S. Deitelzweig, 2016, Current medical research and opinion.

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

J. Ajani, T. Zander, A. Lièvre, 2021 .